InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Estrella Immunopharma, Inc.

ESLA Clue Score19
United States Fiscal year ends December CIK 0001844417
$0.41 -1.80% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.41 −95.86% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 14 Sep 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2021Operating income−0.2Net income−0.2EPS, diluted−1.52Fiscal year 2022Operating income−1.6Net income−1.0Fiscal year 2023Operating income−11.1Net income−11.1EPS, diluted−36.35Fiscal year 2024Operating income−7.3Net income−7.3EPS, diluted−0.27Fiscal year 2025Operating income−13.1Net income−13.1EPS, diluted−0.35
FY2021FY2022FY2023FY2024FY2025
Operating income −0.2 −1.6 −11.1 −7.3 −13.1
Net income −0.2 −1.0 −11.1 −7.3 −13.1
Growth
EPS, diluted −1.52 n/a −36.35 −0.27 −0.35

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2021Operating cash flow−0.3Fiscal year 2022Operating cash flow−1.0Fiscal year 2023Operating cash flow−1.3Fiscal year 2024Operating cash flow−16.1Fiscal year 2025Operating cash flow−1.8
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.3 −1.0 −1.3 −16.1 −1.8

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash0.5Shareholders’ equity−1.0Fiscal year 2022Cash0.0Shareholders’ equity−2.3Fiscal year 2023Cash2.5Shareholders’ equity−11.7Fiscal year 2024Cash4.2Shareholders’ equity4.3Fiscal year 2025Cash1.4Shareholders’ equity−10.4
FY2021FY2022FY2023FY2024FY2025
Cash 0.5 0.0 2.5 4.2 1.4
Shareholders’ equity −1.0 −2.3 −11.7 4.3 −10.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 30 Jun 2023 FY2024 30 Jun 2024 FY2025 31 Dec 2025
Operations
−0.3 −1.0 −1.3 −16.1 −1.8
Growth
Investment
−45.2 36.2 −0.3 5.0 n/a
Financing
46.0 −35.6 n/a 12.8 2.3

Capital expenditure, dividends and buybacks are shown as money out, so negative.